94 related articles for article (PubMed ID: 15501984)
1. Heteroclitic CD33 peptide with enhanced anti-acute myeloid leukemic immunogenicity.
Bae J; Martinson JA; Klingemann HG
Clin Cancer Res; 2004 Oct; 10(20):7043-52. PubMed ID: 15501984
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia.
Bae J; Martinson JA; Klingemann HG
Cell Immunol; 2004 Jan; 227(1):38-50. PubMed ID: 15051513
[TBL] [Abstract][Full Text] [Related]
3. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.
Bae J; Martinson JA; Klingemann HG
Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068
[TBL] [Abstract][Full Text] [Related]
4. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells.
Hauswirth AW; Florian S; Printz D; Sotlar K; Krauth MT; Fritsch G; Schernthaner GH; Wacheck V; Selzer E; Sperr WR; Valent P
Eur J Clin Invest; 2007 Jan; 37(1):73-82. PubMed ID: 17181570
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies.
Balaian L; Ball ED
Leuk Res; 2004 Aug; 28(8):821-9. PubMed ID: 15203280
[TBL] [Abstract][Full Text] [Related]
6. The CD68 protein as a potential target for leukaemia-reactive CTL.
Sadovnikova E; Parovichnikova EN; Savchenko VG; Zabotina T; Stauss HJ
Leukemia; 2002 Oct; 16(10):2019-26. PubMed ID: 12357353
[TBL] [Abstract][Full Text] [Related]
7. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
8. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H
Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways.
Balaian L; Ball ED
Exp Hematol; 2005 Feb; 33(2):199-211. PubMed ID: 15676214
[TBL] [Abstract][Full Text] [Related]
10. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting.
Kügler M; Stein C; Kellner C; Mentz K; Saul D; Schwenkert M; Schubert I; Singer H; Oduncu F; Stockmeyer B; Mackensen A; Fey GH
Br J Haematol; 2010 Sep; 150(5):574-86. PubMed ID: 20636437
[TBL] [Abstract][Full Text] [Related]
11. Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells.
Vitale C; Romagnani C; Puccetti A; Olive D; Costello R; Chiossone L; Pitto A; Bacigalupo A; Moretta L; Mingari MC
Proc Natl Acad Sci U S A; 2001 May; 98(10):5764-9. PubMed ID: 11320212
[TBL] [Abstract][Full Text] [Related]
12. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs.
Nguyen DH; Ball ED; Varki A
Exp Hematol; 2006 Jun; 34(6):728-35. PubMed ID: 16728277
[TBL] [Abstract][Full Text] [Related]
13. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
[TBL] [Abstract][Full Text] [Related]
14. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors.
Biedermann B; Gil D; Bowen DT; Crocker PR
Leuk Res; 2007 Feb; 31(2):211-20. PubMed ID: 16828866
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice.
Distler E; Wölfel C; Köhler S; Nonn M; Kaus N; Schnürer E; Meyer RG; Wehler TC; Huber C; Wölfel T; Hartwig UF; Herr W
Exp Hematol; 2008 Apr; 36(4):451-63. PubMed ID: 18261837
[TBL] [Abstract][Full Text] [Related]
17. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing.
Hernández-Caselles T; Martínez-Esparza M; Pérez-Oliva AB; Quintanilla-Cecconi AM; García-Alonso A; Alvarez-López DM; García-Peñarrubia P
J Leukoc Biol; 2006 Jan; 79(1):46-58. PubMed ID: 16380601
[TBL] [Abstract][Full Text] [Related]
18. Identification of a common HLA-A*0201-restricted epitope among SSX family members by mimicking altered peptide ligands strategy.
He Y; Mao L; Lin Z; Deng Y; Tang Y; Jiang M; Li W; Jia Z; Wang J; Ni B; Wu Y
Mol Immunol; 2008 May; 45(9):2455-64. PubMed ID: 18295890
[TBL] [Abstract][Full Text] [Related]
19. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
[TBL] [Abstract][Full Text] [Related]
20. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]